Rini BI, et al. - Because improved progression-free survival was seen in a phase 2 trial with atezolizumab plus bevacizumab vs sunitinib in patients with metastatic renal cell carcinoma expressing programmed death-ligand 1, researchers reported outcomes of IMmotion151, a phase 3 trial assessing atezolizumab plus bevacizumab vs sunitinib in first-line metastatic renal cell carcinoma. For this multicenter, open-label, randomized controlled trial, study participants were randomly assigned 1:1 to either atezolizumab 1,200 mg plus bevacizumab 15 mg/kg intravenously once every 3 weeks or sunitinib 50 mg orally once daily for 4 weeks on, 2 weeks off. In patients with metastatic renal cell carcinoma, atezolizumab plus bevacizumab prolonged progression-free survival vs sunitinib and had a good safety profile. Long-term follow-up is needed to determine whether there will be a survival benefit. For selected patients with advanced renal cell carcinoma, atezolizumab plus bevacizumab as a first-line treatment option was supported.